On December 23, Gelonghui reported that Sunshine Novo (688621.SH) disclosed the investor relations activity record form, which shows that the integrated R&D service model of 'preclinical + clinical' has significant competitive advantages. This model can fully meet the diverse service needs of clients, thereby enhancing the success rate and efficiency of drug development. This advantage helps to strengthen the company's ability to acquire Orders.

Faced with the current intensifying competition in the Industry, the company has adopted a more proactive market expansion strategy by regularly communicating with clients for project planning to ensure precise alignment of R&D services. So far, the trend for new clients and Orders has been good.